Amikacin Dosing in Pediatrics
For pediatric patients with normal renal function, administer amikacin 15 mg/kg/day divided into 2-3 doses (7.5 mg/kg q12h or 5 mg/kg q8h), with neonates requiring a 10 mg/kg loading dose followed by 7.5 mg/kg q12h, adjusted by gestational and postnatal age. 1
Standard Dosing by Age Group
Neonates (FDA-Approved Regimen)
The FDA label provides the authoritative dosing framework 1:
- Loading dose: 10 mg/kg initially
- Maintenance: 7.5 mg/kg every 12 hours
However, more precise gestational age-based dosing from recent guidelines 2 should guide neonatal therapy:
For gestational age <30 weeks:
- Postnatal age <14 days: 15 mg/kg q48h
- Postnatal age ≥14 days: 15 mg/kg q24h
For gestational age 30-34 weeks:
- Postnatal age <14 days: 15 mg/kg q36h
- Postnatal age ≥14 days: 15 mg/kg q24h
For gestational age ≥34 weeks:
- Postnatal age ≤7 days: 15 mg/kg q24h
- Postnatal age >7 days: 18 mg/kg q24h
Infants and Children (>1 month)
Standard dosing 1:
- 15 mg/kg/day total, divided as either:
- 7.5 mg/kg IV q12h, OR
- 5 mg/kg IV q8h
- Maximum daily dose: 1.5 grams/day regardless of weight
Once-daily dosing alternative 2:
- 15-22.5 mg/kg IV q24h
- Supported by research showing 20 mg/kg once daily achieves appropriate peaks (49-54 mg/L) and troughs (6-8 mg/L) 3
Dosing in Renal Impairment
Two FDA-approved adjustment methods 1:
Method 1: Extended Interval (Preferred for Stability)
Calculate dosing interval by multiplying serum creatinine (mg/dL) by 9:
- Example: If SCr = 2 mg/dL, give 7.5 mg/kg q18h
Method 2: Reduced Dose at Fixed Interval
- Give 7.5 mg/kg loading dose
- Maintenance dose = (Observed CrCl / Normal CrCl) × Loading dose, given q12h
- Simplified alternative: Divide normal dose by serum creatinine value
Critical caveat: Neither method should be used during dialysis 1
Therapeutic Drug Monitoring Requirements
Mandatory monitoring parameters 1:
Target Concentrations
- Peak (30-90 min post-infusion): <35 mcg/mL (avoid exceeding)
- Trough (just before next dose): <10 mcg/mL (avoid exceeding)
- Optimal therapeutic peaks: 15-30 mcg/mL for efficacy
- Optimal troughs: <1-2 mcg/mL to minimize toxicity
High-Risk Populations Requiring Closer Monitoring
Recent research identifies specific populations with altered pharmacokinetics 4:
- Burn patients: Higher clearance, may need increased doses
- Cystic fibrosis: Increased volume of distribution and clearance
- Oncology/febrile neutropenia: May require higher initial doses
- Premature infants: Weight, postmenstrual age, and renal function significantly affect clearance 5
Administration Guidelines
Infusion parameters 1:
- Adults: 30-60 minutes
- Pediatric patients: 30-60 minutes
- Infants: 1-2 hours (longer infusion reduces peak-related toxicity)
Do not mix amikacin with other drugs in the same solution 1
Duration and Safety Monitoring
Treatment duration 1:
- Standard: 7-10 days
- If >10 days required: Re-evaluate necessity and monitor:
- Serum amikacin levels
- Renal function (creatinine, BUN)
- Auditory function
- Vestibular function
Toxicity risk factors 6:
- Concomitant vancomycin significantly increases nephrotoxicity risk
- Critical illness alters pharmacokinetics
- Lower trough concentrations reduce nephrotoxicity, though optimal threshold remains undefined
Clinical Pitfalls to Avoid
Premature infants: Standard 15 mg/kg/day is often inadequate; use gestational age-based dosing 2, 5
Weight-only dosing limitations: Kidney maturation (not just weight) drives aminoglycoside clearance in early life 7. Infants show >65% variation in trough attainment within the first year despite weight-based dosing.
Renal function assessment: Use creatinine clearance or serum creatinine, NOT BUN 1
Peak timing variability: In neonates, peak time ranges 17-60 minutes depending on dose 8; adjust sampling accordingly
Subtherapeutic dosing in special populations: Children with malignancies may need 20 mg/kg/day divided q6h to maintain therapeutic levels 9
Guideline Context
WHO guidelines position amikacin as a second-choice agent for neonatal sepsis, combined with cloxacillin, cefotaxime, or ceftriaxone, while gentamicin remains first-line 10. This reflects amikacin's role in resistant Gram-negative infections rather than empiric first-line therapy.